Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Random

Display 15 Products per page

Byetta
Read More
Byetta (exenatide; AstraZeneca) is a member of the glucagon-like peptide-1 (GLP-1) agonist class.
November 7, 2017
Find out more
MOR208
Read More
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant.
October 9, 2018
Find out more
Pristiq
Read More
Pristiq (desvenlafaxine; Pfizer) is purely a follow-on product to the former leading serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant Effexor (venlafaxine; Pfizer).
March 29, 2019
Find out more
Enhertu
Read More
Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca) is an antibody-drug conjugate composed of a monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2), an enzymatically cleavable peptide-linker, and a topoisomerase 1 inhibitor derived from exatecan. The drug-to-antibody ratio of Enhertu is 8:1.
February 26, 2020
Find out more
Gantenerumab
Read More
Gantenerumab (Roche/MorphoSys) is a fully humanized centrally and N-acting monoclonal antibody that primarily targets fibrillar amyloid-beta.
September 2, 2016
Find out more
Glembatumumab Vedotin
Read More
Glembatumumab vedotin (Celldex) is an antibody–drug conjugate that targets cancer cells expressing glycoprotein non-metastatic B.
April 15, 2016
Find out more
Oral Vidaza
Read More
Oral Vidaza is an orally available formulation of Vidaza (azacitidine; Celgene/Nippon Shinyaku), a small molecule cytidine nucleoside analog that exerts its anti-cancer activity through direct cytotoxicity as well as through DNA hypomethylation.
July 6, 2017
Find out more
Votrient
Read More
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis
March 6, 2019
Find out more
Lebrikizumab
Read More
Lebrikizumab (Roche/Chugai) is a humanized monoclonal antibody that binds to interleukin (IL)-13. IL-13 induces bronchial epithelial cells to secrete periostin, a matricellular protein.
May 12, 2016
Find out more
Kinenza
Read More
Kinenza (enzastaurin) is an oral serine/threonine kinase inhibitor that suppresses signaling of protein kinase C (PKC)-beta to induce cell apoptosis, reduce cell proliferation, and suppress tumor-induced angiogenesis.
October 9, 2018
Find out more
Imlygic
Read More
Imlygic (talimogene laherparepvec; Amgen) is a gene-deleted oncolytic herpes simplex virus-1 (HSV-1) that encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF). Upon administration, Imlygic replicates selectively in tumor cells and generates GM-CSF.
May 23, 2018
Find out more
Prevnar 13
Read More
Prevnar 13 is Pfizer’s follow-on vaccine to Prevnar 7, which was the first pneumococcal conjugate vaccine licensed in the US.
December 21, 2018
Find out more
Abraxane
Read More
Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.
February 26, 2020
Find out more
Copaxone
Read More
Copaxone is an immunomodulator composed of four amino acids found in myelin basic protein, believed to act by modifying immune processes in the pathogenesis of MS. It was the third disease-modifying MS drug to be available in the US, following its April 1997 launch.
November 24, 2017
Find out more
Iomab-B
Read More
Iomab-B is a radioimmunotherapy comprised of the monoclonal antibody BC8 coupled with the radioisotope Iodine-131.
July 6, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *